23:33 , Oct 6, 2017 |  BC Extra  |  Company News

Management tracks: Impel, InGeneron

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc. , which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company...
20:35 , Apr 21, 2017 |  BC Week In Review  |  Company News

Alpine, Nivalis deal

Immunology company Alpine will reverse-merge cystic fibrosis play Nivalis in a stock deal. The combined entity will retain Alpine’s name and will trade on NASDAQ under a new ticker. Alpine’s current CEO, Mitchell Gold, will...
23:24 , Apr 18, 2017 |  BC Extra  |  Company News

Alpine finds public path through Nivalis

Immunology company Alpine Immune Sciences Inc. (Seattle, Wash.) and cystic fibrosis play Nivalis Therapeutics Inc. (NASDAQ:NVLS) said they will merge in an all-stock transaction. Upon the deal's close, expected in 3Q17, the combined company will...
07:00 , Sep 16, 2016 |  BC Extra  |  Company News

Management tracks

EMA said Head of International Affairs Emer Cooke will leave the agency to join the World Health Organization as head of regulation of medicines and other health technologies in WHO's essential medicines and health products...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Financial News

Alpine Immune Sciences completes venture financing

Alpine Immune Sciences Inc. , Seattle, Wash.   Business: Cancer, Autoimmune, Infectious   Date completed: 2016-06-13   Type: Venture financing   Raised: $48 million   Investors: OrbiMed Advisors; Frazier & Co.; Alpine BioVentures  ...
07:00 , Jun 20, 2016 |  BioCentury  |  Finance

Mountain of cash

Investors in Alpine Immune Sciences Inc. decided the company's A round had to get the preclinical immunotherapy company to human efficacy data. The syndicate therefore is pouring in $48 million, about double the average size...
01:14 , Jun 14, 2016 |  BC Extra  |  Financial News

Alpine raises $48M series A round

Alpine Immune Sciences Inc. (Seattle, Wash.) raised $48 million in a series A round led by OrbiMed Advisors. Frazier Healthcare Partners and seed investor Alpine BioVentures also participated. Alpine is developing multispecific proteins to achieve...
08:00 , Feb 8, 2016 |  BioCentury  |  Emerging Company Profile

Immune orchestration

Alpine Immune Sciences Inc. is developing multispecific proteins to achieve the effects of immunotherapy combinations, but with more control and using a single molecule. The company's vIgD platform is based upon endogenous proteins that exist...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

Alpine Immune Sciences, Kite Pharma deal

Alpine granted Kite exclusive, worldwide rights to develop and commercialize chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies against two undisclosed cancer targets using Alpine’s transmembrane immunomodulatory protein (TIP) platform. Alpine will receive...
02:07 , Oct 28, 2015 |  BC Extra  |  Company News

Kite, Alpine partner in immuno-oncology

Alpine Immune Sciences Inc. (Seattle, Wash.) granted Kite Pharma Inc. (NASDAQ:KITE) an exclusive, worldwide license to develop and commercialize chimeric antigen receptor (CAR) and T cell receptor ( TCR ) therapies against two undisclosed cancer...